These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31466070)

  • 41. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
    Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
    BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is it effective to perform two more prostate biopsies according to prostate-specific antigen level and prostate volume in detecting prostate cancer? Prospective study of 10-core and 12-core prostate biopsy.
    Yoon BI; Shin TS; Cho HJ; Hong SH; Lee JY; Hwang TK; Kim SW
    Urol J; 2012; 9(2):491-7. PubMed ID: 22641493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.
    Chiu PK; Roobol MJ; Teoh JY; Lee WM; Yip SY; Hou SM; Bangma CH; Ng CF
    Int Urol Nephrol; 2016 Oct; 48(10):1631-7. PubMed ID: 27349564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    Zheng S; Jiang S; Chen Z; Huang Z; Shi W; Liu B; Xu Y; Guo Y; Yang H; Li M
    PLoS One; 2019; 14(11):e0218645. PubMed ID: 31743339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges.
    Meshref AW; Bazinet M; Trudel C; Aronson S; Peloquin F; Nachabe M; Dessureault J; Aprikian AG; Begin LR; Elhilali MM
    Urology; 1995 Jun; 45(6):972-9. PubMed ID: 7539562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate Volume Index Associates with a Decreased Risk of Prostate Cancer: Results of a Large Cohort of Patients Elected to a First Biopsy Set.
    Porcaro AB; Novella G; Cacciamani G; De Marchi D; Corsi P; De Luyk N; Bizzotto L; Processali T; Cerasuolo M; Tamanini I; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Urol Int; 2017; 98(1):22-27. PubMed ID: 27376763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
    Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
    Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.
    García-Cruz E; Huguet J; Piqueras M; Márquez MP; Peri L; Izquierdo L; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    World J Urol; 2012 Jun; 30(3):361-5. PubMed ID: 21833558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
    Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
    Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
    Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy.
    Karakiewicz PI; Benayoun S; Bégin LR; Duclos A; Valiquette L; McCormack M; Bénard F; Saad F; Perrotte P
    Int J Clin Pract; 2007 Mar; 61(3):425-30. PubMed ID: 17313610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is PSA density still useful in diagnosing prostate cancer?
    Pepe P; Candiano G; Fraggetta F; Galia A; Grasso G; Allegro R; Aragona F
    Arch Ital Urol Androl; 2009 Dec; 81(4):199-202. PubMed ID: 20608140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
    Greene DJ; Elshafei A; Nyame YA; Kara O; Malkoc E; Gao T; Jones JS
    Prostate; 2016 Aug; 76(11):1019-23. PubMed ID: 27197726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transition Zone Prostate-specific Antigen Density Could Better Guide the Rebiopsy Strategy in Men With Prostate Inflammation at Initial Biopsy.
    Amini E; Pishgar F; Ayati M; Jamshidian H; Arbab A; Gooshe M; Nowroozi MR
    Urology; 2015 Nov; 86(5):985-90. PubMed ID: 26284593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.